PSMA CAR Immune Cells for Targeted Metastatic Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic interventions for metastatic prostate cancer are highly ineffective, necessitating the need for targeted treatment strategies.
Innovation Solution
Development of recombinant nucleic acid sequences encoding chimeric antigen receptors (CARs) with specific binding domains for prostate-specific membrane antigen (PSMA) to engineer T cells and NK cells for targeted immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic interventions are used for metastatic prostate cancer, then treatment is broadly applicable, but effectiveness is highly ineffective
Solution Approach 1:
The patent applies local quality by engineering T cells with chimeric antigen receptors (CARs) that specifically recognize PSMA expressed on prostate cancer cells. This creates localized specificity at the molecular level - the CAR-PSMA interaction occurs only at the interface between engineered T cells and PSMA-positive tumor cells, leaving other tissues unaffected. This resolves the contradiction by providing high effectiveness through targeted recognition while maintaining broad applicability through systemic administration of the engineered cells.
Solution Approach 2:
The patent employs parameter changes by modifying the immunological parameters of T cells through genetic engineering. The T cells are transformed from conventional immune cells into targeted effectors by introducing CAR constructs with specific PSMA-binding domains. This changes the recognition parameters of the immune system, enabling it to specifically identify and eliminate prostate cancer cells while sparing normal tissues, thereby achieving both high effectiveness and controlled versatility.
2Adaptability or versatility
If conventional T cell therapy is used, then the approach is simple to implement, but it lacks specific targeting capability for PSMA
Solution Approach 1:
The patent applies segmentation by dividing the CAR construct into functional domains: a PSMA-binding domain (antigen recognition), a transmembrane domain (cellular anchoring), and signaling domains (activation). This modular segmentation allows for systematic engineering of T cell specificity - each domain can be independently optimized and assembled, making the complex engineering process more manageable while achieving precise PSMA targeting.
Solution Approach 2:
The patent uses an intermediary approach by introducing CAR-T cells as a bridge between the immune system and PSMA-positive prostate cancer cells. These engineered cells serve as mediators that translate the presence of PSMA into targeted immune activation. The CAR construct acts as an intermediary structure that captures PSMA and converts it into an immunogenic signal, resolving the contradiction between simplicity and specificity by providing a clear mechanistic pathway for targeted recognition.
3Object-affected harmful factors
If non-specific chemotherapy is used, then treatment can be administered broadly, but it causes harm to healthy tissues
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the normally harmful, non-specific cytotoxic activity of T cells into a beneficial, targeted anti-cancer effect. Through CAR engineering, the destructive potential of T cell-mediated cytotoxicity is redirected specifically toward PSMA-positive prostate cancer cells. The same cytotoxic mechanisms that would otherwise cause collateral damage to healthy tissues are now selectively deployed against tumor cells, simultaneously improving treatment efficacy while minimizing harm to normal tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered immune cells effectively target and kill prostate cancer cells, providing a promising therapeutic approach for treating prostate cancer, particularly in metastatic cases.
Implementation Method 1
a prostate-specific membrane antigen (PSMA) binding domain, wherein the PSMA binding domain comprises a heavy chain variable region (VH) comprising an amino acid sequence 90% identity to SEQ ID NO: 12, 16, 20, 24, or 28 and a light chain variable region (VL) comprising an amino acid sequence 90% identity to SEQ ID NO: 14, 18, 22, 26, or 30
Data Source
AI summary
Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.